688222 Hitgen Inc.
- 13.68
- -0.11-0.80%
Hitgen Inc. News
Chengdu Pioneer (688222) “: The recovery of DEL business is expected to bring about long-term growth, and the continued release of good innovation capabilities
Incident: The company released its 2023 annual report and 2024 quarterly report. 1) In 2023, the company achieved operating income of 371 million yuan, an increase of 12.64% over the previous year; net profit to mother was 40.72 million yuan, an increase of 61 over the previous year.
Express News | Chengdu Pioneer collaborated with Pfizer to develop an isoquinolone skeleton synthesis method suitable for DEL
Chengdu Pioneer (688222): DEL core business significantly resumed diversified characteristic platforms to accelerate commercialization
Incident: On April 24, 2024, Chengdu Pioneer released its 2023 annual report. The company achieved annual revenue of 371 million yuan, an increase of 12.64% over the previous year; net profit to mother was 407.18,500 yuan, an increase of 61.
Minsheng Securities released a research report on April 25 stating that it gave Chengdu Xiandao (688222.SH) a recommended rating. The main reasons for the rating include: 1) the DEL screening and library customization business has recovered significantly,
Minsheng Securities released a research report on April 25 stating that it gave Chengdu Xiandao (688222.SH) a recommended rating. The main reasons for the rating include: 1) the DEL screening and library customization business has recovered significantly, continuously improving novelty and service diversification; 2) the diversified technology platform gradually shows commercial value and strengthens the company's new drug discovery and optimization capabilities; 3) R&D investment focuses on platform upgrades and iterations and key pipelines, and AI accelerates the efficiency of drug development. (Mainichi Keizai Shimbun)
Chengdu Pioneer (688222.SH) announced its 2023 annual results, with net profit of 40.72 million yuan, an increase of 61.16% over the previous year
Chengdu Pioneer (688222.SH) disclosed its 2023 annual report, and the company achieved revenue of 3 in 2023...
The A-share CRO sector collectively rebounded, and Xuantai Pharmaceutical rose more than 15%
Gelonghui, April 17 | Xuantai Pharmaceutical rose more than 15%, while stocks such as Yuanbio, Chengdu Pioneer, Wisdom Pharmaceuticals, Haite Biotech, and Baihua Pharmaceuticals rose more than 5%. According to the news, Xuantai Pharmaceutical predicts a 201% year-on-year increase in net profit for the first quarter. In addition, Frost & Sullivan predicts that the global CRO market is expected to be about 96 billion US dollars in 2024, of which the segmented clinical CRO market accounts for the largest share, accounting for about 64% in 2022, the market size is about 51.4 billion US dollars, and is expected to grow to 62.2 billion US dollars in 2024. Furthermore, China's CRO market is growing faster than the global market.
Are HitGen Inc.'s (SHSE:688222) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
It is hard to get excited after looking at HitGen's (SHSE:688222) recent performance, when its stock has declined 22% over the past three months. It seems that the market might have completely ignor
Chengdu Pilot (688222.SH): AI models are all self-developed or jointly developed with partners, and there is no external procurement
Gelonghui, March 21丨Chengdu Xiandao (688222.SH) said on the interactive platform that at present, Chengdu Pilot's AI technology mainly focuses on molecular discovery and optimization, training and iteration of experimental data based on large model+DEL screening test data, aimed at expanding the space of compounds with multiple target types, generating new molecules, improving compound properties, and increasing compound accessibility. The AI models pioneered in Chengdu were all developed in-house or jointly with partners, and there was no external procurement. As far as traditional Internet companies are concerned, the characteristics of Chengdu Pioneer in AI pharmaceuticals are: 1) Pilot's AI model has a larger number of actual experiments
Chengdu Pilot (688222.SH): Exploring various AI drug prediction, molecular generation, and optimization models
GLONGHUI, March 21丨Chengdu Xiandao (688222.SH) said on an interactive platform that in 2021, the company and Cambridge Molecular (Cambridge Small Molecule) announced the establishment of an exclusive alliance to efficiently provide potentially active, more readily available compounds for drug targets and accelerate compounds on Chengdu's leading DNA-coding Compound Library (DEL) technology platform, in combination with Cambridge Molecular's highly optimized deep machine learning system for DEL Verification of activity and widening of compound emptiness
A-shares CRO concept stocks fluctuated and declined
Gelonghui, March 21 | Hongbo Pharmaceutical and Chengdu Pioneer fell more than 4%, while many stocks such as Medici, Wisdom Pharmaceutical, and Wanbang Pharmaceutical fell.
Market Participants Recognise HitGen Inc.'s (SHSE:688222) Revenues Pushing Shares 42% Higher
HitGen Inc. (SHSE:688222) shares have had a really impressive month, gaining 42% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the losses of the la
Chengdu Pioneer (688222): DEL recovers significantly, R&D expenses continue to remain high
Incident: The company released the 2023 performance report. In 2023, the company achieved operating income of 372 million yuan, an increase of 12.74% over the previous year; net profit to mother was 43.94 million yuan, an increase of 73.92% over the previous year; deducted
The DEL sector of the core business recovered significantly, and Chengdu Pioneer's net profit in 2023 increased 73.92% year-on-year
① In the fourth quarter of last year, the company achieved revenue of 126 million yuan, realized net profit of 25.6571 million yuan, and deducted non-net profit of 3.048 million yuan. ② During the reporting period, the DEL sector of the company's core business recovered significantly, and the increase in operating income led to an increase in profit for the current period. ③ In 2023, the company invested 80.42 million yuan in R&D, accounting for 22% of revenue. Compared with 2022 investment, the year-on-year decrease was 8%.
Does HitGen (SHSE:688222) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Chengdu Pioneer (688222.SH) performance report: 2023 net profit of 43.9437 million yuan, a year-on-year increase of 73.92%
On February 23, Ge Longhui (688222.SH) announced the 2023 annual results report. During the reporting period, the company achieved operating income of 371.6596 million yuan, an increase of 12.74% year on year; achieved net profit attributable to the owner of the parent company of 43.94 million yuan, an increase of 73.92% year on year; realized net profit attributable to the owner of the parent company after deducting non-recurring profit and loss of 3.297,700 yuan, a year-on-year decrease of 73.61%.
Hox Therapeutics and Vernalis Announce a Drug Discovery Collaboration in Oncology
CHENGDU, China, Feb. 20, 2024 /PRNewswire/ -- Hox Therapeutics Ltd ("Hox") a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd ("Vernalis"), a fully owne
Chengdu Pilot (688222.SH): Juntian Investment and Juntian Venture Capital reduced their total shareholding by 4.40%, and their shareholding ratio fell below 5%
Gelonghui, Feb. 19 | Chengdu Pioneer (688222.SH) announced that the company recently received the “Simplified Equity Change Report” from Juntian Investment and Juntian Venture Capital. From May 13, 2021 to February 8, 2024, Juntian Investment and Juntian Venture Capital reduced their holdings of the company's unrestricted tradable shares by a total of 176.33,800 shares through centralized bidding transactions and bulk transactions, accounting for 4.40% of Chengdu Xiandao's total share capital; after this change in equity, the above entities held 4.999991% of the company's shares. East.
Chengdu Pioneer (688222): The new molecule discovery platform has obvious advantages and significant business development results
Chengdu Pioneer: A leader in DEL technology, the new molecule discovery platform has obvious advantages. With DEL technology as the core, the company has built a new drug discovery and optimization platform around small molecules and new nucleic acid drugs. The company has built DEL, FBDD/SB
Chengdu Pioneer (688222): DEL business resumed significant technical capabilities were further enhanced
The company predicts a 50-98% increase in net profit in 2023 The company released a performance forecast: in 2023, revenue of 365-380 million yuan, an increase of 10.72-15.27% over the previous year, and 0.38-0 net profit to mother
Chengdu Pilot (688222.SH): Net profit is expected to increase by 50.4% to 97.89% year-on-year in 2023
Gelonghui, January 29丨Chengdu Pilot (688222.SH) announced that it is expected to achieve operating revenue of 365.0 million yuan to 380.01 million yuan in 2023. Compared with the same period last year, it will increase 353.5 million yuan to 50.35 million yuan, an increase of 10.72% to 15.27% over the previous year. The net profit attributable to the owners of the parent company is expected to be 38.0 million yuan to 50 million yuan in 2023, an increase of 12.734 million yuan to 24.734 million yuan compared with the same period last year, an increase of 12.734 million yuan to 24.734 million yuan, an increase over the previous year
Analysis
Price Target
No Data
